According to Jiu'an Medical's announcement, the cumulative deviation value of the company's stock price increase exceeded 20% for 2 consecutive trading days on July 15 and 16, 2026, which is an abnormal fluctuation. The company's fundamentals have not changed, and the stock price is affected by market sentiment, etc. The company's investment in science and innovation has no capital guarantee or minimum return guarantee, and there is a risk of project investment failure and loss. The company expects net profit of 2.8 billion to 3.4 billion yuan for the half-year 2026. The performance is affected by the revenue from the science and innovation investment layout. Furthermore, the subsidiary Jiu'an Hong Kong indirectly invests 750 million yuan in Hangzhou and holds about 0.21% of the shares. There is a risk that commercial returns will fall short of expectations.

According to Jiu'an Medical's announcement, the cumulative deviation value of the company's stock price increase exceeded 20% for 2 consecutive trading days on July 15 and 16, 2026, which is an abnormal fluctuation. The company's fundamentals have not changed, and the stock price is affected by market sentiment, etc. The company's investment in science and innovation has no capital guarantee or minimum return guarantee, and there is a risk of project investment failure and loss. The company expects net profit of 2.8 billion to 3.4 billion yuan for the half-year 2026. The performance is affected by the revenue from the science and innovation investment layout. Furthermore, the subsidiary Jiu'an Hong Kong indirectly invests 750 million yuan in Hangzhou and holds about 0.21% of the shares. There is a risk that commercial returns will fall short of expectations.